This basic science study aims to elucidate the structural and biochemical requirements for the catalytic activity of soluble guanylate cyclase, a key enzyme in cardiovascular regulation.
Advances sGC mechanistic insights; extends preclinical knowledge but leaves clinical translation open.
Background Soluble guanylate cyclase (sGC) is the key enzyme in the NO-sGC-cGMP signaling cascade crucial in regulating the cardiovascular system. Low output of this system causes hypertension and acute heart failure, which are the leading causes of death globally. Mammalian sGC is a heterodimer. Each of the two homologous subunits (a and b) contains three domains: an N-terminal regulatory domain (HNOX: Heme Nitric oxide OXygen), a central dimerization HNOX associated (HNOXA) and coiled-coil (CC) domain, and a C-terminal catalytic domain (GC). The enzyme is basally active, but NO binding to the heme group in the b subunit’s regulatory domain enhances sGC catalytic output several hundred fold. The exact mechanism by which the regulatory domain relays the NO activation signal to the catalytic domain remains elusive. Furthermore, it has been proposed that the HNOX regulatory domain inhibits the activity of the catalytic GC domain [1]. Winger et al. showed that the GC heterodimer by itself exhibits catalytic activity in the presence of Mg and Mn[1]. On the contrary, Wedel et al. propose that additional amino acids are required for dimerization, folding, and catalytic activity [2]. We aim to test the hypothesis that additional domains are necessary for full activity of the catalytic domain by combining mutagenesis, activity assays, fluorescence spectroscopy, Small-Angle X-ray Scattering (SAXS), and protein crystallography.
No takes yet. Share an insight, caveat, or question.
Seeger et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: